Psychosocial functioning during the treatment of major depressive disorder with fluoxetine

George I. Papakostas, Timothy Petersen, John W. Denninger, Eliana Tossani, Joel A. Pava, Jonathan E. Alpert, Andrew A. Nierenberg, Maurizio Fava

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Background: Major depressive disorder (MDD) is associated with significant disability, having a profound impact on psychosocial functioning. Therefore, studying the impact of treatment on psychosocial functioning in MDD could help further improve the standard of care. Methods: Two hundred twenty-two MDD outpatients were treated openly with 20 mg fluoxetine for 8 weeks. The self-report version of the Social Adjustment Scale was administered at baseline and during the final visit. We then tested for the relationships between (1) self-report version of the Social Adjustment Scale scores at baseline and clinical response, (2) nonresponse, response and remission status and overall psychosocial adjustment at end point, (3) the number/ severity of residual depressive symptoms and overall psychosocial adjustment at end point in responders, and (4) the time to onset of response and overall psychosocial adjustment at end point. Results: An earlier onset of clinical response predicted better over-all psychosocial functioning at end point (P = 0.0440). Responders (n = 128) demonstrated better overall psychosocial adjustment at end point than nonresponders (P = 0.0003), while remitters (n = 64) demonstrated better overall psychosocial adjustment at end point than nonremitted responders (P = 0.0031). In fact, a greater number/ severity of residual symptoms predicted poorer overall psychosocial adjustment at end point in responders (P = 0.0011). Psychosocial functioning at baseline did not predict response. Conclusions: While MDD patients appear equally likely to respond to treatment with fluoxetine, regardless of their level of functioning immediately before treatment, the above results stress the importance of achieving early symptom improvement then followed by full remission of depressive symptoms with respect to restoring psychosocial functioning in MDD.

Original languageEnglish (US)
Pages (from-to)507-511
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume24
Issue number5
DOIs
StatePublished - Oct 2004
Externally publishedYes

Fingerprint

Social Adjustment
Fluoxetine
Major Depressive Disorder
Therapeutics
Self Report
Depression
Standard of Care
Outpatients

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. / Papakostas, George I.; Petersen, Timothy; Denninger, John W.; Tossani, Eliana; Pava, Joel A.; Alpert, Jonathan E.; Nierenberg, Andrew A.; Fava, Maurizio.

In: Journal of Clinical Psychopharmacology, Vol. 24, No. 5, 10.2004, p. 507-511.

Research output: Contribution to journalArticle

Papakostas, GI, Petersen, T, Denninger, JW, Tossani, E, Pava, JA, Alpert, JE, Nierenberg, AA & Fava, M 2004, 'Psychosocial functioning during the treatment of major depressive disorder with fluoxetine', Journal of Clinical Psychopharmacology, vol. 24, no. 5, pp. 507-511. https://doi.org/10.1097/01.jcp.0000138761.85363.d5
Papakostas, George I. ; Petersen, Timothy ; Denninger, John W. ; Tossani, Eliana ; Pava, Joel A. ; Alpert, Jonathan E. ; Nierenberg, Andrew A. ; Fava, Maurizio. / Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. In: Journal of Clinical Psychopharmacology. 2004 ; Vol. 24, No. 5. pp. 507-511.
@article{7dd5f42920dc4d0b84faa119c46b5101,
title = "Psychosocial functioning during the treatment of major depressive disorder with fluoxetine",
abstract = "Background: Major depressive disorder (MDD) is associated with significant disability, having a profound impact on psychosocial functioning. Therefore, studying the impact of treatment on psychosocial functioning in MDD could help further improve the standard of care. Methods: Two hundred twenty-two MDD outpatients were treated openly with 20 mg fluoxetine for 8 weeks. The self-report version of the Social Adjustment Scale was administered at baseline and during the final visit. We then tested for the relationships between (1) self-report version of the Social Adjustment Scale scores at baseline and clinical response, (2) nonresponse, response and remission status and overall psychosocial adjustment at end point, (3) the number/ severity of residual depressive symptoms and overall psychosocial adjustment at end point in responders, and (4) the time to onset of response and overall psychosocial adjustment at end point. Results: An earlier onset of clinical response predicted better over-all psychosocial functioning at end point (P = 0.0440). Responders (n = 128) demonstrated better overall psychosocial adjustment at end point than nonresponders (P = 0.0003), while remitters (n = 64) demonstrated better overall psychosocial adjustment at end point than nonremitted responders (P = 0.0031). In fact, a greater number/ severity of residual symptoms predicted poorer overall psychosocial adjustment at end point in responders (P = 0.0011). Psychosocial functioning at baseline did not predict response. Conclusions: While MDD patients appear equally likely to respond to treatment with fluoxetine, regardless of their level of functioning immediately before treatment, the above results stress the importance of achieving early symptom improvement then followed by full remission of depressive symptoms with respect to restoring psychosocial functioning in MDD.",
author = "Papakostas, {George I.} and Timothy Petersen and Denninger, {John W.} and Eliana Tossani and Pava, {Joel A.} and Alpert, {Jonathan E.} and Nierenberg, {Andrew A.} and Maurizio Fava",
year = "2004",
month = "10",
doi = "10.1097/01.jcp.0000138761.85363.d5",
language = "English (US)",
volume = "24",
pages = "507--511",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Psychosocial functioning during the treatment of major depressive disorder with fluoxetine

AU - Papakostas, George I.

AU - Petersen, Timothy

AU - Denninger, John W.

AU - Tossani, Eliana

AU - Pava, Joel A.

AU - Alpert, Jonathan E.

AU - Nierenberg, Andrew A.

AU - Fava, Maurizio

PY - 2004/10

Y1 - 2004/10

N2 - Background: Major depressive disorder (MDD) is associated with significant disability, having a profound impact on psychosocial functioning. Therefore, studying the impact of treatment on psychosocial functioning in MDD could help further improve the standard of care. Methods: Two hundred twenty-two MDD outpatients were treated openly with 20 mg fluoxetine for 8 weeks. The self-report version of the Social Adjustment Scale was administered at baseline and during the final visit. We then tested for the relationships between (1) self-report version of the Social Adjustment Scale scores at baseline and clinical response, (2) nonresponse, response and remission status and overall psychosocial adjustment at end point, (3) the number/ severity of residual depressive symptoms and overall psychosocial adjustment at end point in responders, and (4) the time to onset of response and overall psychosocial adjustment at end point. Results: An earlier onset of clinical response predicted better over-all psychosocial functioning at end point (P = 0.0440). Responders (n = 128) demonstrated better overall psychosocial adjustment at end point than nonresponders (P = 0.0003), while remitters (n = 64) demonstrated better overall psychosocial adjustment at end point than nonremitted responders (P = 0.0031). In fact, a greater number/ severity of residual symptoms predicted poorer overall psychosocial adjustment at end point in responders (P = 0.0011). Psychosocial functioning at baseline did not predict response. Conclusions: While MDD patients appear equally likely to respond to treatment with fluoxetine, regardless of their level of functioning immediately before treatment, the above results stress the importance of achieving early symptom improvement then followed by full remission of depressive symptoms with respect to restoring psychosocial functioning in MDD.

AB - Background: Major depressive disorder (MDD) is associated with significant disability, having a profound impact on psychosocial functioning. Therefore, studying the impact of treatment on psychosocial functioning in MDD could help further improve the standard of care. Methods: Two hundred twenty-two MDD outpatients were treated openly with 20 mg fluoxetine for 8 weeks. The self-report version of the Social Adjustment Scale was administered at baseline and during the final visit. We then tested for the relationships between (1) self-report version of the Social Adjustment Scale scores at baseline and clinical response, (2) nonresponse, response and remission status and overall psychosocial adjustment at end point, (3) the number/ severity of residual depressive symptoms and overall psychosocial adjustment at end point in responders, and (4) the time to onset of response and overall psychosocial adjustment at end point. Results: An earlier onset of clinical response predicted better over-all psychosocial functioning at end point (P = 0.0440). Responders (n = 128) demonstrated better overall psychosocial adjustment at end point than nonresponders (P = 0.0003), while remitters (n = 64) demonstrated better overall psychosocial adjustment at end point than nonremitted responders (P = 0.0031). In fact, a greater number/ severity of residual symptoms predicted poorer overall psychosocial adjustment at end point in responders (P = 0.0011). Psychosocial functioning at baseline did not predict response. Conclusions: While MDD patients appear equally likely to respond to treatment with fluoxetine, regardless of their level of functioning immediately before treatment, the above results stress the importance of achieving early symptom improvement then followed by full remission of depressive symptoms with respect to restoring psychosocial functioning in MDD.

UR - http://www.scopus.com/inward/record.url?scp=4644294076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644294076&partnerID=8YFLogxK

U2 - 10.1097/01.jcp.0000138761.85363.d5

DO - 10.1097/01.jcp.0000138761.85363.d5

M3 - Article

VL - 24

SP - 507

EP - 511

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 5

ER -